Overview

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

Status:
Unknown status

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

The study is designed to demonstrate the therapeutic non-inferiority of the recombinant humanized monoclonal VEGF antibody bevacizumab administered by intravitreal injection in the treatment of AMD in comparison to the related fragment ranibizumab.

Phase:

Phase 3

Details

Lead Sponsor:

Klinikum Bremen-Mitte, gGmbH

Collaborator:

Kompetenzzentrum für Klinische Studien, Bremen

Treatments:

Bevacizumab
Ranibizumab